Skip to main content

Table 1 Clinical data

From: Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

Parameters Values Description and reference
Weibull survival model of RFS for surgery only   
 1-97 weeks Scale = 0.001554; Shape = 1.202; r2 = 0.9955 [2]
 Beyond 97 weeks Scale = 0.02754; Shape = 0.5736; r2 = 0.9792 [2]
Weibull survival model of OS for surgery only   
 1-141 weeks Scale = 0.00005097; Shape = 1.755; r2 = 0.9977 [2]
 Beyond 141 weeks Scale = 0.005259; Shape = 0.8171; r2 = 0.9935 [2]
HR of RFS (compared with surgery only)   
 Adjuvant with S-1 0.653 (95% CI: 0.537-0.793) [2]
 Adjuvant with XELOX strategy# 0.58 (95% CI: 0.47–0.72) [27]
HR of OS (compared with surgery only)   [2]
 Adjuvant with S-1 0.669 (95% CI: 0.54-0.828)  
 Adjuvant with XELOX strategy 0.66 (95% CI: 0.51–0.85) [27]
  1. #We assumed that DFS in the CLASSIC trial was not better than RFS.